Jasper Therapeutics: Successful Preliminary Studies Cause Stock Price to Rise

The stock of biotechnology company Jasper Therapeutics is on the rise on Monday after the company announced preliminary data from its ongoing SPOTLIGHT Phase 1b/2a study. This study is investigating the subcutaneous administration of Briquilimab in adults with cold urticaria or symptomatic dermographism. An impressive 93% of study participants in both dosing cohorts showed a clinical response within the six-week analysis period. The response was particularly convincing in the 120 mg cohort, where 83% of the participants recorded a complete response. Encouragingly, Briquilimab was well-tolerated by participants, with no serious adverse events or unwanted events of category 3 or higher reported. This paved the way for Jasper to receive approval to further test a higher dose (180 mg). Looking ahead, Jasper plans to present the full SPOTLIGHT study data in the first half of 2025. In parallel, the company expects to release initial results from the BEACON study in the week of January 6, 2025. These will also include the recently added 180 mg dosing cohort. Some notable clinical observations from the study include significant reductions in tryptase levels. These correlated with the onset of clinical responses and were particularly evident after two weeks in the 120 mg cohort. Thanks to this positive news, Jasper's stock rose by 5.93% to $15.90 before trading began on Monday.